Agios Pharmaceuticals (NASDAQ:AGIO) Given New $32.00 Price Target at The Goldman Sachs Group

Agios Pharmaceuticals (NASDAQ:AGIO) had its target price hoisted by The Goldman Sachs Group from $28.00 to $32.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price target suggests a potential downside of 6.88% from the stock’s previous close.

Several other research firms also recently commented on AGIO. Wall Street Zen upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. Leerink Partners upped their price objective on Agios Pharmaceuticals from $34.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, December 26th. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Friday. Citigroup lifted their target price on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Finally, Truist Financial boosted their target price on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, December 24th. Six research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $41.44.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO traded up $0.53 during mid-day trading on Wednesday, hitting $34.36. 765,496 shares of the stock traded hands, compared to its average volume of 910,291. The company has a market cap of $2.01 billion, a PE ratio of -4.84 and a beta of 0.89. Agios Pharmaceuticals has a twelve month low of $22.24 and a twelve month high of $46.00. The firm has a 50 day simple moving average of $28.47 and a two-hundred day simple moving average of $32.17.

Insider Activity

In other news, insider Tsveta Milanova sold 2,872 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $27.02, for a total value of $77,601.44. Following the completion of the sale, the insider owned 34,793 shares of the company’s stock, valued at approximately $940,106.86. This represents a 7.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Krishnan Viswanadhan sold 2,959 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $27.80, for a total value of $82,260.20. Following the completion of the transaction, the insider directly owned 5,141 shares in the company, valued at approximately $142,919.80. This represents a 36.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of AGIO. Bellevue Group AG boosted its stake in shares of Agios Pharmaceuticals by 3.5% in the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock valued at $149,110,000 after purchasing an additional 124,586 shares during the last quarter. State Street Corp increased its position in shares of Agios Pharmaceuticals by 37.4% during the fourth quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after buying an additional 845,433 shares during the period. Erste Asset Management GmbH raised its stake in Agios Pharmaceuticals by 1.4% during the fourth quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock worth $76,343,000 after buying an additional 40,000 shares during the last quarter. Wellington Management Group LLP raised its stake in Agios Pharmaceuticals by 485.5% during the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock worth $99,203,000 after buying an additional 2,049,287 shares during the last quarter. Finally, Commodore Capital LP lifted its holdings in Agios Pharmaceuticals by 0.6% in the third quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company’s stock valued at $93,859,000 after buying an additional 13,287 shares during the period.

Key Stories Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Agios said it will pursue U.S. accelerated approval for mitapivat in sickle cell disease after a pre‑sNDA meeting with the FDA; the company plans to submit the sNDA in coming months and has already proposed a confirmatory trial. Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease
• Positive Sentiment: Analysts and media reported regulatory feedback as a clear pathway toward accelerated approval, which triggered a sharp intraday rally on hopes of earlier label expansion and revenue upside. AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD
• Positive Sentiment: Commercial update: early uptake of Agios’ Aqvesme in thalassemia shows promising clinician interest (up to ~1/3 of patients seen as candidates), supporting longer‑term revenue diversification. PK Activation Gains Momentum in Thalassemia
• Neutral Sentiment: Coverage notes the stock’s recent above‑average volume and earnings‑estimate revision trend, implying analysts are re‑rating the story but cautioning on sustainability. Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?
• Neutral Sentiment: An insider sale of roughly $82k in AGIO stock was reported; the firm notes context matters (small dollar size vs. company market cap). Insider Sells AGIO Shares Worth $82,000 — But Context Is Everything
• Negative Sentiment: Levi & Korsinsky launched an investigation into possible securities‑law violations related to Agios’ RISE UP topline results, creating legal and disclosure overhang. Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
• Negative Sentiment: The Gross Law Firm also opened an investigation into potential securities fraud claims tied to the same disclosures, adding to litigation risk. AGIO ALERT- The Gross Law Firm Has Commenced an Investigation
• Negative Sentiment: Technically, AGIO recently slipped below its 200‑day moving average, which can attract short‑term selling pressure from technical traders. Agios Pharmaceuticals (NASDAQ:AGIO) Stock Passes Below 200 Day Moving Average

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.